Omaha, NE Clinical Trials Report — June 2026

For Omaha residents considering participation in clinical research, June 2026 brings important opportunities, particularly for those who can act quickly. Across Omaha, NE, a total of 21 clinical trials are slated to conclude their enrollment within the next 90 days. This urgency is especially relevant for healthy volunteers, as 5 of these rapidly closing studies are still actively seeking participants without specific health conditions, offering a chance to contribute to medical advancements before their enrollment windows close.

Upcoming Deadlines for Research Participation

Patients managing specific health conditions also have limited time to join research studies. Trials focused on various conditions are among those with impending deadlines for enrollment. Conditions with trials closing soon include:

• Peripheral arterial disease (2 trials)
• Prostate cancer (2 trials)
• Advanced malignant neoplasm (1 trial)
• AML (1 trial)
• AML with mutated NPM1 (1 trial)
• Amnio-Maxx (1 trial)
• Atopic dermatitis (1 trial)
• Amniotic band syndrome (1 trial)
• Autoimmune bullous dermatosis (1 trial)
• Benign prostatic hyperplasia (BPH) (1 trial)

New Research Opportunities in Omaha

This month, Omaha saw the opening of 9 new clinical trials, an increase from the 6 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Omaha, NE, to 584 across 225 research facilities, highlighting the city's active role in medical research.

June's new trials are diverse, with 7 focusing on new drug therapies, 2 on medical devices, and 1 classified as "other" research. These studies are exploring a range of conditions, with the most frequent being:

• Type 2 diabetes mellitus (2 trials)
• Overweight (2 trials)
• Obesity (2 trials)
• Chronic weight management (2 trials)
• Creativity and mindfulness (1 trial)
• Dry eye disease (DED) (1 trial)
• Dry eye syndrome (DES) (1 trial)
• Emotion management skills (1 trial)
• Exercise and recovery (1 trial)
• Exercise training (1 trial)

Notable sponsors driving these new studies include AstraZeneca and Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Overall, 6 of the new trials are sponsored by industry, with 3 from other sources, including academic institutions.

Spotlight on Key Phase 3 Drug Trials

Several significant Phase 3 drug trials have opened in Omaha this month, offering participants the chance to engage with cutting-edge treatments from major sponsors:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is sponsoring NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• Also from Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a randomized, double-blind, placebo-controlled Phase 3 study involving 1,100 participants. It will evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus.
• AstraZeneca is leading NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This Phase 3 study aims for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with Type 2 Diabetes Mellitus and increased cardiovascular risk.
• Another AstraZeneca-sponsored Phase 3 trial is NCT07662135, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This study seeks 900 participants to evaluate elecoglipron's efficacy, safety, and tolerability in adults with Type 2 Diabetes Mellitus and impaired renal function already on dapagliflozin.
• For prostate cancer research, PROCEPT BioRobotics is sponsoring NCT07650448, "WATER IV PCa (AS Sub-study)." This study aims for 333 participants to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to research. Of the 9 new trials launched this month, 2 are actively seeking healthy volunteers. Across Omaha, a total of 51 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Omaha's Leading Research Facilities

Omaha is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Nebraska Medical Center (208 trials)
• Alegent Health Bergan Mercy Medical Center (41 trials)
• Nebraska Medicine-Village Pointe (40 trials)
• Nebraska Cancer Specialists (39 trials)
• Alegent Health Lakeside Hospital (38 trials)
• Alegent Health Immanuel Medical Center (38 trials)
• Nebraska Methodist Hospital (31 trials)
• Children's Hospital and Medical Center of Omaha (29 trials)
• Research Site (24 trials)
• Creighton University Medical Center (22 trials)

The University of Nebraska Medical Center stands out as a major hub, running significantly more trials than any other facility in the city, indicating a broad range of research specializations. Facilities like Nebraska Cancer Specialists and Children's Hospital and Medical Center of Omaha also highlight specialized areas of research within the city.

Broadening Your Search: Nearby Options in Nebraska

While Omaha offers a robust selection of clinical trial opportunities, individuals may also find options in other communities within Nebraska. Compared to Omaha's 584 trials, nearby cities with active trials include Lincoln (6 trials), Grand Island (1 trial), and Kearney (1 trial). This demonstrates Omaha's significant role as a leading research center in the state.

Participation in clinical trials is open to a diverse range of individuals. Of the 9 new trials launched this month, all 9 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, 1 is female-only, and 1 is male-only, reflecting varied eligibility criteria across studies.

As we move through June, Omaha's active research community continues to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare. Those interested in participating, especially in trials closing soon or those seeking healthy volunteers, are encouraged to explore these options promptly.